Tuesday 23rd December 2008
|Text too small?|
As part of the deal, Keratec's chief science officer Rob Kelly will provide his services via his own company. After the transaction, Keratec will write off biomedical IP of about NZ$600,000 while parent Wool Equities will write of goodwill in Keratec of NZ$1.3 million.
The all-up impact is a NZ$1.9 million non-cash expense for Wool Equities of NZ$1.9 million and remaining Keratec IP still owned by the company of NZ$750,000. In turn it gets potential sales, up to a point of NZ$8 million, when the percentage of its share halves.
The company has been downsizing after the sale of its Covita and Paraco units to Crown Research Institute AgResearch. A spokesman for the company couldn't immediately be reached.
Wool Equities last traded at 26 cents on Oct. 16.
No comments yet
7th December 2021 Morning Report
Sky Network Television Limited (NZX: SKY) Transformation accelerates - Sky raises FY22 guidance
PGG Wrightson Limited (NZX: PGW) FY22 Operating EBITDA forecast to better last year
Vulcan Steel Limited (NZX: VSL) Trading Update & Earnings Upgrade
6th December 2021 Morning Report
Synlait Milk Limited (NZX: SML) Partnership to enhance soil health; test regen ag practices
Property for Industry Limited (NZX: PFI) Strong Valuation Outcome, Penrose Acquisition
3rd December 2021 Morning Report
Fonterra Shareholders Fund (NZX: FSF) Fonterra provides Milk Price, earnings and Q1 update
Kiwi Property Group Limited (NZX: KPG) Signs Sale and Purchase Agreement with IKEA